Vaccine

OSE Immunotherapeutics strengthens Growth Strategy:  Accelerates key pillars of Inflammation and Immuno-OncologyOSE Immunotherapeutics strengthens Growth Strategy:  Accelerates key pillars of Inflammation and Immuno-Oncology

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

Figure_1 Figure 1: Clinical Remission rate observed in all-comers population and sub-population according to composite IL7R axis biomarker in CoTikiS…

6 days ago
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today…

6 days ago
FSA Store® Issues Alert for June 30 flexible spending account (FSA) Spending Deadline: Check Your Balance and Use, Don’t Lose, Tax-free FundsFSA Store® Issues Alert for June 30 flexible spending account (FSA) Spending Deadline: Check Your Balance and Use, Don’t Lose, Tax-free Funds

FSA Store® Issues Alert for June 30 flexible spending account (FSA) Spending Deadline: Check Your Balance and Use, Don’t Lose, Tax-free Funds

FSA Store recommends three steps to help account holders avoid forfeiting unused funds to the June 30 deadline – a…

6 days ago
Press Release:  ASCO: new Sarclisa data support subcutaneous administration with on-body injectorPress Release:  ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered…

7 days ago
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 StudyIMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented…

7 days ago
Rapid Dose Announces Completion of Share Issuance in Debt Settlement with CreditorsRapid Dose Announces Completion of Share Issuance in Debt Settlement with Creditors

Rapid Dose Announces Completion of Share Issuance in Debt Settlement with Creditors

Burlington, Ontario--(Newsfile Corp. - June 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced…

1 week ago
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial ApplicationsDyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable…

1 week ago
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast CancerArvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to…

1 week ago
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of ShareholdersCOSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today…

1 week ago